SS-31 Protocol: Dosing, Timing, and What Research Shows

The SS-31 protocol is a research-use dosing plan for elamipretide, a mitochondria-targeted tetrapeptide studied for cellular energy production and oxidative stress. Most protocols described in labs and research communities use roughly 1–10 mg injected subcutaneously once daily or several times per week, usually cycled 4–8 weeks on with a break afterward. SS-31 is not FDA-approved for human use in the United States, so any protocol is experimental and should be reviewed with a licensed healthcare professional.

What SS-31 (Elamipretide) Actually Is

SS-31 is a synthetic four-amino-acid peptide — D-Arg-Dmt-Lys-Phe-NH2 — also known as elamipretide, MTP-131, and Bendavia. It is designed to concentrate in the inner mitochondrial membrane, where it binds cardiolipin, a phospholipid that helps organize the electron transport chain.

In preclinical models, that binding is linked to improved ATP production, lower reactive oxygen species, and better mitochondrial structural integrity. Those findings are why the peptide appears in discussions about cardiac function, skeletal muscle performance, and age-related mitochondrial decline.

Human data is thinner. Elamipretide has been tested in clinical trials for Barth syndrome, primary mitochondrial myopathy, and dry age-related macular degeneration, with mixed results and at least one FDA complete response letter. It remains a research chemical, not an approved drug.

Typical SS-31 Dosing Ranges

Dosing varies widely because no standard human protocol exists. Published trials and community reports cluster into a few recognizable patterns.

Reported ss-31 peptide dosage ranges from 1 mg to 40 mg per day depending on whether the reference point is a community protocol or a trial protocol. A basic ss-31 peptide protocol usually starts at the low end and increases only if the researcher documents stable tolerance.

Whether a source calls it an ss-31 dosing protocol or simply an SS-31 schedule, the numbers involved are usually the same. Community write-ups often split the weekly total into two or three smaller injections rather than one large dose, though no comparative data shows that splitting improves outcomes.

Reconstitution, Storage, and Handling

SS-31 ships as a lyophilized powder and must be reconstituted before use.

• Use bacteriostatic water or sterile water; add the liquid slowly down the vial wall to avoid foaming.
• A 10 mg vial mixed with 2 mL of water yields 5 mg/mL; a 50 mg vial with 5 mL yields 10 mg/mL.
• Swirl gently — never shake — until the powder fully dissolves.
• Store lyophilized vials at -20°C, protected from light.
• Keep reconstituted solution refrigerated at 2–8°C and use within about four to six weeks.
• Inspect for cloudiness or particles and discard the vial if either appears.

These are general lab-handling steps, not medical instructions. Anyone handling the peptide should follow their supplier's or institution's documentation.

Cycle Length and Timing

SS-31 has a short plasma half-life — minutes to a few hours in animal studies — which is why once-daily or multiple-times-weekly dosing is common. Tissue accumulation at the mitochondrial membrane is thought to last longer than plasma levels suggest.

Most community protocols run 4 to 8 weeks on, followed by 2 to 4 weeks off. The rationale for cycling is largely precautionary: long-term human safety data is limited, and many researchers prefer to cap cumulative exposure until more is known.

Timing within the day is generally treated as flexible. Some researchers dose in the morning to align with natural circadian peaks in mitochondrial activity; others split doses across the day.

Reported SS-31 Peptide Benefits in Research

The reported ss-31 peptide benefits in preclinical work center on mitochondrial energy output, reduced oxidative stress, and preserved function in cardiac and skeletal muscle tissue. Animal models of ischemia-reperfusion injury, heart failure, and sarcopenia have shown improvements on those markers.

Human evidence is narrower and more mixed:

• Barth syndrome trials showed gains in some functional and cardiac measures but did not meet every primary endpoint.
• The MMPOWER trial in primary mitochondrial myopathy missed its primary six-minute walk endpoint.
• Ophthalmic trials for dry AMD have not produced consistent visual improvements.

Nothing here supports claims that SS-31 treats, cures, or prevents any disease. Anyone considering it should treat it as experimental and discuss risks with a physician.

Stacking and Related Protocols

Some researchers pair mitochondrial agents, and an ss-31 and mots-c protocol is sometimes discussed as a way to combine a cardiolipin-binding peptide with a mild mitochondrial uncoupler. No human trial data covers that combination, and both compounds are research chemicals, so stacking multiplies unknown variables rather than resolving them.

Others combine SS-31 with NAD+ precursors or recovery-oriented peptides. Each addition makes it harder to attribute an observed effect to a single compound.

Safety, Side Effects, and Legal Status

SS-31 is not FDA-approved for human use in the United States. It is sold as a research chemical, and products labeled "for research use only" are not held to pharmaceutical manufacturing standards, so purity and identity can vary by vendor.

Reported side effects in trials include injection-site reactions, headache, nausea, and dizziness, and most were mild. Long-term safety data in healthy people does not exist.

• Buy only from vendors that publish third-party certificates of analysis for each lot.
• Avoid use during pregnancy, breastfeeding, or in anyone under 18.
• Do not combine with other injectable peptides without medical supervision.
• Seek medical care for chest pain, severe headache, or signs of an allergic reaction.

SS-31 is a research peptide, not an approved therapy. No protocol replaces evaluation by a licensed healthcare professional.

Bottom Line

The SS-31 protocol is best understood as an experimental framework, not a standardized treatment. Typical research dosing falls between 1 mg and 10 mg subcutaneously per day or several times per week, cycled over 4 to 8 weeks, with 40 mg daily representing the high end used in elamipretide trials.

Because human data is limited and regulatory approval has not been granted, the most defensible approach is low starting exposure, careful record-keeping, verified product quality, and medical oversight.